BEAM Stock Price Today (October 2026) — Beam Therapeutics Inc. Analysis & Key Metrics 2026-10-07
Beam Therapeutics Inc. (BEAM) is trading at $24.77, down 1.82% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $52.15 (110.5% upside).
- Volatility is moderate (32.98% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-94.20% YoY) alongside competitive pressures in the Biotechnology space.
BEAM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Beam Therapeutics Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.65B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+110.5% upside potential
Key Investor Questions About BEAM
What investors need to know before buying
Based on current market data, BEAM presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 46.33)
- Fundamentals say: Challenging (declining revenue trends)
BEAM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BEAM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $247.36M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, BEAM stock traded between $20.23 and $38.26 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 32.98% annualized volatility and β=2.24, the stock exhibits high sensitivity to market moves—making BEAM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Beam Therapeutics (BEAM) Stock Could Trade At A Premium As Gene Editing Interest Grows
Beam Therapeutics sits in a crowded gene editing field, and its share price history raises a simple question for you as an investor: Is the current US$24.37 price properly reflecting what the business is generating in sales today? Over the past 5 years the stock has fallen 72.1%, which puts the focus squarely on whether the revenue it produces can still justify even the current market value. Recent coverage of the in vivo gene editing market highlights Beam Therapeutics as a key participant...
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit?
Beam Therapeutics Inc. (NASDAQ:BEAM) reported updated Phase 1/2 results on September 8 for BEAM-302, an investigational gene-editing treatment for alpha-1 antitrypsin deficiency, or AATD. Although 38 patients had been treated by August 17, the presented efficacy analysis covered 29 single-dose patients at the June 24 cutoff. Biomarker results extended to 18 months, while overall patient […]
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
Beam Therapeutics Inc. (NASDAQ:BEAM) on Tuesday presented updated Phase 1/2 trial data for BEAM-302, an experimental base-editing therapy for alpha-1 antitrypsin deficiency (AATD). AATD is a hereditary disorder caused by low levels of protective AAT protein, leading to lung damage (emphysema, COPD) and liver disease. The company shared these findings at the European Respiratory Society Congress 2026, showcasing the genetic medicine’s potential to directly correct the root cause of both liver and
Beam Therapeutics (BEAM) Stock May Look Stretched As Sales Expectations Climb
Beam Therapeutics has delivered a sharp 86.5% share price gain over the past year, yet the stock screens as expensive on broader valuation checks, which leaves recent buyers paying up for its gene editing potential without clear support from traditional metrics. The 86.5% 1 year return highlights how strongly sentiment has swung in favor of Beam Therapeutics, even though the business is still early in its commercial journey. Expectations that Beam Therapeutics can eventually turn its gene...
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics posts a wider-than-expected Q2 loss. Revenues also miss estimates as it advances multiple genome-editing programs with key clinical milestones ahead.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of -18.00% and -98.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Explore More Analysis for BEAM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Beam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) is currently trading at $24.77. The RSI (14-day) is at 46.3, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $52.15 implies 110.5% upside from current levels. Volatility is moderate at 33.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Beam Therapeutics Inc. (BEAM): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 2.26. Price-to-Sales is 15.97. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 13 analysts covering BEAM, the consensus price target is $52.15. This represents a 110.5% upside from the current price of $24.77. The range spans from a low target of $26.00 to a high target of $80.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Beam Therapeutics Inc. (BEAM) investors include: 1. Moderate volatility (33.0% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Declining revenue (-94.2% YoY), indicating potential business headwinds. 4. Elevated short interest (38.8% of float) suggests significant bearish sentiment. 5. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 6. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Beam Therapeutics Inc.'s (BEAM) current debt and financial health profile: Total debt stands at $247.36M. The debt-to-equity ratio is 0.23x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 14.57, indicating strong short-term liquidity. The quick ratio is 14.25. The company holds $1.15B in cash and equivalents. Free cash flow is negative at -$241.84M, which could limit the company's ability to manage debt obligations.